Characteristics of Medicaid Recipients Receiving Persistent Antipsychotic Polypharmacy

Overview

Journal Community Ment Health J

Specialty Health Services

Date 2017 Nov 12

PMID 29127560

Citations 6

Authors

Robert O Cotes

David R Goldsmith

Sarah L Kopelovich

Cathy A Lally

Benjamin G Druss

Affiliations

Soon will be listed here.

Abstract

Antipsychotic polypharmacy (APP) is a common strategy despite guidelines advising against this practice. This article seeks to quantify the prevalence and correlates of APP using Medicaid Analytic eXtract files from 2003 to 2004. Nineteen percent of Medicaid recipients who received an antipsychotic were treated with APP. Individuals who received APP were more likely to be white, male, disabled, between the ages of 18-29, diagnosed with a psychotic disorder, and diagnosed with a higher number of psychiatric conditions. Geographic variation in APP rates was also observed. Quality improvement initiatives may help reduce APP for medically vulnerable patients.

Citing Articles

Characterization of antipsychotic utilization before clozapine initiation for individuals with schizophrenia: an innovative visualization of trajectories using French National Health Insurance data.

Laforgue E, Istvan M, Chaslerie A, Artarit P, Vallot G, Jolliet P Epidemiol Psychiatr Sci. 2023; 32:e59.

PMID: 37723967 PMC: 10539739. DOI: 10.1017/S2045796023000732.

Antipsychotics and Medical Comorbidity: A Retrospective Study in an Urban Outpatient Psychiatry Clinic.

Bennett C, Gensler L, Goldsmith D Community Ment Health J. 2022; 59(4):641-653.

PMID: 36355255 DOI: 10.1007/s10597-022-01045-2.

Cluster Analysis of Clozapine Consumer Perspectives and Comparison to Consumers on Other Antipsychotics.

Sharma S, Kopelovich S, Janjua A, Pritchett C, Broussard B, Dhir M Schizophr Bull Open. 2021; 2(1):sgab043.

PMID: 34676369 PMC: 8521287. DOI: 10.1093/schizbullopen/sgab043.

A Comparison of Attitudes, Comfort, and Knowledge of Clozapine Among Two Diverse Samples of US Psychiatrists.

Cotes R, Janjua A, Broussard B, Lazris D, Khan A, Jiao Y Community Ment Health J. 2021; 58(3):517-525.

PMID: 34052963 PMC: 9112232. DOI: 10.1007/s10597-021-00847-0.

Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients.

Toto S, Hefner G, Hahn M, Hiemke C, Roll S, Wolff J J Neural Transm (Vienna). 2021; 128(2):263-272.

PMID: 33439364 DOI: 10.1007/s00702-020-02298-5.

References

Sneider B, Pristed S, Correll C, Nielsen J . Frequency and correlates of antipsychotic polypharmacy among patients with schizophrenia in Denmark: A nation-wide pharmacoepidemiological study. Eur Neuropsychopharmacol. 2015; 25(10):1669-76. DOI: 10.1016/j.euroneuro.2015.04.027. View

Jeste D, Caligiuri M, Paulsen J, Heaton R, Lacro J, Harris M . Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Arch Gen Psychiatry. 1995; 52(9):756-65. DOI: 10.1001/archpsyc.1995.03950210050010. View

Sabin J, Daniels N . Managed care: improving psychiatric drug benefit management: I. Lessons from Massachusetts. Psychiatr Serv. 2003; 54(7):949-51. DOI: 10.1176/appi.ps.54.7.949. View

Moore T, Buchanan R, Buckley P, Chiles J, Conley R, Crismon M . The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update. J Clin Psychiatry. 2007; 68(11):1751-62. DOI: 10.4088/jcp.v68n1115. View

Nielsen J, le Quach P, Emborg C, Foldager L, Correll C . 10-year trends in the treatment and outcomes of patients with first-episode schizophrenia. Acta Psychiatr Scand. 2010; 122(5):356-66. DOI: 10.1111/j.1600-0447.2010.01576.x. View

Gallego J, Bonetti J, Zhang J, Kane J, Correll C . Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009. Schizophr Res. 2012; 138(1):18-28. PMC: 3382997. DOI: 10.1016/j.schres.2012.03.018. View

Correll C, Shaikh L, Gallego J, Nachbar J, Olshanskiy V, Kishimoto T . Antipsychotic polypharmacy: a survey study of prescriber attitudes, knowledge and behavior. Schizophr Res. 2011; 131(1-3):58-62. PMC: 3159758. DOI: 10.1016/j.schres.2011.02.016. View

Stroup T, Gerhard T, Crystal S, Huang C, Olfson M . Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv. 2013; 65(2):186-92. DOI: 10.1176/appi.ps.201300180. View

Seabury S, Goldman D, Kalsekar I, Sheehan J, Laubmeier K, Lakdawalla D . Formulary restrictions on atypical antipsychotics: impact on costs for patients with schizophrenia and bipolar disorder in Medicaid. Am J Manag Care. 2014; 20(2):e52-60. View

10.

Sweeney J, Keilp J, Haas G, Hill J, Weiden P . Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Res. 1991; 37(3):297-308. DOI: 10.1016/0165-1781(91)90065-w. View

11.

Buchanan R, Kreyenbuhl J, Kelly D, Noel J, Boggs D, Fischer B . The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 2009; 36(1):71-93. PMC: 2800144. DOI: 10.1093/schbul/sbp116. View

12.

Stahl S . Antipsychotic polypharmacy: evidence based or eminence based?. Acta Psychiatr Scand. 2002; 106(5):321-2. DOI: 10.1034/j.1600-0447.2002.2e011.x. View

13.

Vinogradov S, Fisher M, Warm H, Holland C, Kirshner M, Pollock B . The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia. Am J Psychiatry. 2009; 166(9):1055-62. PMC: 3735363. DOI: 10.1176/appi.ajp.2009.09010017. View

14.

Gilmer T, Dolder C, Folsom D, Mastin W, Jeste D . Antipsychotic polypharmacy trends among Medicaid beneficiaries with schizophrenia in San Diego County, 1999-2004. Psychiatr Serv. 2007; 58(7):1007-10. DOI: 10.1176/ps.2007.58.7.1007. View

15.

Tirupati S, Chua L . Obesity and metabolic syndrome in a psychiatric rehabilitation service. Aust N Z J Psychiatry. 2007; 41(7):606-10. DOI: 10.1080/00048670701392841. View

16.

Wu E, Shi L, Birnbaum H, Hudson T, Kessler R . Annual prevalence of diagnosed schizophrenia in the USA: a claims data analysis approach. Psychol Med. 2006; 36(11):1535-40. DOI: 10.1017/S0033291706008191. View

17.

Correll C . Acute and long-term adverse effects of antipsychotics. CNS Spectr. 2008; 12(12 Suppl 21):10-4. DOI: 10.1017/s1092852900015959. View

18.

Lehman A, Lieberman J, Dixon L, McGlashan T, Miller A, Perkins D . Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004; 161(2 Suppl):1-56. View

19.

Covell N, Jackson C, Evans A, Essock S . Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull. 2002; 28(1):17-29. DOI: 10.1093/oxfordjournals.schbul.a006920. View

20.

Ganguly R, Kotzan J, Miller L, Kennedy K, Martin B . Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry. 2004; 65(10):1377-88. DOI: 10.4088/jcp.v65n1013. View